SEC Form 4 · accession 0001209191-15-055750
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William D Baird III
Officer — Chief Financial Officer
Period of report
Jun 19, 2015
Accepted (ET)
Jun 23, 2015 · 8:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Jun 19, 2015 | M | 5,080 | $13.2627 | A | 61,655 | D | |
| Common stockF2 | Jun 19, 2015 | M | 2,655 | $13.2627 | A | 64,310 | D | |
| Common stockF2 | Jun 19, 2015 | M | 7,500 | $13.2627 | A | 71,810 | D | |
| Common stockF3 | Jun 19, 2015 | S | 15,235 | $13.2627 | D | 56,575 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $3.53 | Jun 19, 2015 | M | 5,080 | D | Jan 28, 2014 | Jan 28, 2023 | Common stock | 5,080 | 43,340 | D |
| Stock Options (right to buy) | $2.52 | Jun 19, 2015 | M | 2,655 | D | Jun 18, 2014 | Jun 18, 2023 | Common stock | 2,655 | 48,879 | D |
| Stock Options (right to buy) | $2.45 | Jun 19, 2015 | M | 7,500 | D | Jan 3, 2015 | Jan 3, 2024 | Common stock | 7,500 | 75,000 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.16 to $13.33. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.16 to $13.33. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.